Giulia Varvarà

Giulia Varvarà

Auto-generated profile, based on publicly available information

Giulia Varvarà

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S, Rennes, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
GVGiulia Varvarà
Giulia Varvarà
CBCora Burgwinkel
Cora Burgwinkel
CLClara Locher
Clara Locher
JRJoseph S. Ross
Joseph S. Ross
UMUlrich Mansmann
Ulrich Mansmann
FNFlorian Naudet
Florian Naudet

10 August 2026 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
EEEmma Escoffier
Emma Escoffier
UMUlrich Mansmann
Ulrich Mansmann
NDNicholas J. DeVito
Nicholas J. DeVito
FNFlorian Naudet
Florian Naudet

7 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CBCora Burgwinkel
Cora Burgwinkel
HCHan Chang Chiam
Han Chang Chiam
KTKa Hin Tai
Ka Hin Tai
JWJifan Wang
Jifan Wang
MAMian Haider Ali
Mian Haider Ali
LHLeonhard Held
Leonhard Held
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.

22 October 2026 in BMC Medicine
Verified
Journal Article
Open access
PDF file
UMUlrich Mansmann
Ulrich Mansmann
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
FNFlorian Naudet
Florian Naudet
Background: Clinical trial data sharing is increasingly endorsed by journals, funders, regulators, and research organisations. Nevertheless, access to individual participant data (IPD) remains inconsistent and may not be available when trial results are published. Access timelines can reflect several distinct components, including scientific and governance review, contractual and legal procedures, data preparation, de-identification, transfer, and subsequent harmonisation. When original data are unavailable, researchers may reconstruct approximate participant-level event-time data from published Kaplan-Meier curves. Trinquart and Stockler recently proposed that trialists instead release minimal analysable time-to-event data at publication. Their proposal raises a broader question: what kinds of data and documentation are required for different forms of reproducibility and scientific reuse? Main text: We argue that clinical trial data transparency should be considered in relation to the scientific claims and research activities that a particular data object can support. We propose a three-tier framework for data intentionally released or made accessible by trialists or data custodians. Tier 1 comprises original publication-time reduced datasets and supports endpoint-level numerical reproducibility and analyses that are functions of the released observations. Tier 2 comprises reproducibility packages containing analysis-ready data, code, derivation logic, and documentation sufficient to reproduce the reported analytic process. Tier 3 provides governed access to broader de-identified IPD for substantively new analyses and reassessment of operational and analytic decisions. Reconstructed pseudo-IPD are considered separately because they are generated externally from publications rather than shared from the trial database. Privacy protection, governance, and processing environment are cross-cutting dimensions and do not map uniquely to a particular tier. They also apply differently to each tier. Conclusions: Publication-time reduced datasets can provide meaningful and timely transparency when broader IPD are not yet accessible. Their value should be recognised without confusing endpoint-level numerical reproducibility with reproduction of the complete analytic process or broader scientific reuse. We propose that publication-time reduced datasets should form a practical floor for timely transparency, while reproducibility packages and governed access to broader IPD provide progressively richer opportunities for reproducing, interrogating, and extending clinical trial analyses.

30 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
EEEmma Escoffier
Emma Escoffier
UMUlrich Mansmann
Ulrich Mansmann
NDNicholas J. DeVito
Nicholas J. DeVito
FNFlorian Naudet
Florian Naudet
ObjectiveTo map the presence, public availability, and content of clinical trial data sharing policies, data management and sharing plans, and data use agreements among the most prolific public and private clinical trial sponsors operating in Europe. Eligibility criteriaWe included organisation-level documents describing approaches to clinical trial data sharing or data management from the top 20 public and top 20 private sponsors ranked by the number of trials registered in the EU Clinical Trials Information System. Eligible materials comprised publicly available or sponsor-shared policies, guidelines, statements, templates, and agreements relevant to clinical trial data sharing or management. Sources of evidenceEvidence was identified through systematic searches of sponsors’ public websites, structured Google searches, and major data management plan platforms, complemented by direct contact with sponsors to verify findings and request missing documentation. All sources were archived and catalogued. Charting methodsTwo reviewers independently extracted data using a structured form, capturing the existence, accessibility, and content of data sharing policies, data management and sharing plans, and data use agreements. Quantitative data were summarised descriptively, and a non-interpretive descriptive content analysis was conducted to characterise recurring policy elements and areas of heterogeneity. ResultsAmong 40 sponsors, private sponsors were substantially more likely than public sponsors to make trial-specific data sharing policies and data use agreements publicly accessible, often via established data sharing platforms. Public sponsors more frequently referenced data management and sharing plans, but these were heterogeneous in scope and often embedded within broader institutional governance documents rather than tailored to clinical trials. Across sectors, General Data Protection Regulation compliance, data protection, and legal safeguards were emphasised, while operational aspects such as dataset readiness, review criteria, and downstream responsibilities varied widely. Overall response rate to sponsor verification was 37.5%. ConclusionClinical trial data sharing governance in the EU shows a marked sectoral imbalance among the top sponsors. Private sponsors tend to provide more detailed and operationally explicit documentation, whereas public sponsors often articulate high-level commitments without trial-specific guidance. Greater clarity and standardisation, particularly among public sponsors, could improve transparency and facilitate responsible data reuse, while remaining compatible with GDPR requirements.

1 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
EEEmma Escoffier
Emma Escoffier
UMUlrich Mansmann
Ulrich Mansmann
NDNicholas J. DeVito
Nicholas J. DeVito
FNFlorian Naudet
Florian Naudet
Objective: To map the presence, public availability, and content of clinical trial data sharing policies (DSP), data management and sharing plans (DMSP), and data use agreements (DUA) among the most prolific public and private clinical trial sponsors operating in the European Union, and to identify key areas of convergence, divergence, and constraint in the context of General Data Protection Regulation (GDPR). Eligibility criteria: We included organisation-level documents describing approaches to clinical trial data sharing or data management from the top 20 public and top 20 private sponsors ranked by the number of trials registered in the EU Clinical Trials Information System (CTIS). Eligible materials comprised publicly available or sponsor-shared policies, guidelines, statements, templates, and agreements relevant to clinical trial data sharing or management. Sources of evidence: Evidence was identified through systematic searches of sponsors’ public websites, structured Google searches, and major data management plan platforms (DMPTool, DMPonline, DMP Assistant), complemented by direct contact with sponsors to verify findings and request missing documentation. All sources were archived and catalogued. Charting methods: Two reviewers independently extracted data using a structured form, capturing the existence, accessibility, and content of data sharing policies, data management and sharing plans, and data use agreements. Quantitative data were summarised descriptively, and a non-interpretive descriptive content analysis was conducted to characterise recurring policy elements and areas of heterogeneity. Results: Among 40 sponsors, private sponsors were substantially more likely than public sponsors to make trial-specific data sharing policies and data use agreements publicly accessible, often via established data sharing platforms. Public sponsors more frequently referenced data management and sharing plans, but these were heterogeneous in scope and often embedded within broader institutional governance documents rather than tailored to clinical trials. Across sectors, GDPR compliance, data protection, and legal safeguards were emphasised, while operational aspects such as dataset readiness, review criteria, and downstream responsibilities varied widely. Overall response rate to sponsor verification was 37.5%. Conclusion: Clinical trial data sharing governance in the EU shows a marked sectoral imbalance among the top sponsors. Private sponsors tend to provide more detailed and operationally explicit documentation, whereas public sponsors often articulate high-level commitments without trial-specific guidance. Greater clarity and standardisation, particularly among public sponsors, could improve transparency and facilitate responsible data reuse, while remaining compatible with GDPR requirements.